EXACT Therapeutics AS - Notice of Annual General Meeting 2022

OSLO/LONDON, 30th May 2022: The Annual General Meeting of EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), will be held as a virtual meeting at 10:30 CEST on 8th June 2022.

The notice of the Annual General Meeting with Attendance/Proxy forms, including the Board of Directors' proposed resolutions for the items listed on the agenda and the 2021 Annual Report are attached. The documents are also available at www.exact-tx.com. The deadline for receiving proxies or attendance registration is 6th June 2022 at 12:00 CEST.

ENDS

Appendices:
Please see here for the full Norwegian-English dual language notice with appendices. 
Please see here for the 2021 Annual Report.

For more information, please contact: 

Masha Strømme, Executive Chair
Exact Therapeutics
Email: Masha@exact-tx.com

Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.

Previous
Previous

EXACT Therapeutics AS: Minutes of Annual General Meeting 2022

Next
Next

EXACT Therapeutics AS Board Update